GlaxoSmithKline and CureVac to make Covid vaccines targeting new variants

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>GlaxoSmithKline has said it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of Covid-19 amid concerns that some mutations are making the virus harder to combat&period;<&sol;p>&NewLine;<p>The UK-based drug maker plans to invest 150 million euros &lpar;£132 million&rpar; to support the research of CureVac&comma; which is developing vaccines that use messenger RNA to attack the disease&period;<&sol;p>&NewLine;<p>GSK also said it will help make up to 100 million doses of the company’s existing Covid-19 vaccine candidate this year&period;<&sol;p>&NewLine;<blockquote class&equals;"twitter-tweet" data-width&equals;"550" data-dnt&equals;"true">&NewLine;<p lang&equals;"en" dir&equals;"ltr"><a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;News&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;News<&sol;a> for <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;investors&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;investors<&sol;a> and <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;media&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;media<&sol;a>&colon; We’ve announced a new collaboration&comma; building on our relationship with <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;CureVacRNA&quest;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&commat;CureVacRNA<&sol;a>&comma; in an effort to jointly develop next-generation mRNA candidate vaccines for <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;hashtag&sol;COVID19&quest;src&equals;hash&amp&semi;ref&lowbar;src&equals;twsrc&percnt;5Etfw">&num;COVID19<&sol;a>&period; <a href&equals;"https&colon;&sol;&sol;t&period;co&sol;HNhJRnQLnA">https&colon;&sol;&sol;t&period;co&sol;HNhJRnQLnA<&sol;a> <a href&equals;"https&colon;&sol;&sol;t&period;co&sol;vbgSJEdCbP">pic&period;twitter&period;com&sol;vbgSJEdCbP<&sol;a><&sol;p>&NewLine;<p>&mdash&semi; GSK &lpar;&commat;GSK&rpar; <a href&equals;"https&colon;&sol;&sol;twitter&period;com&sol;GSK&sol;status&sol;1356862098874241024&quest;ref&lowbar;src&equals;twsrc&percnt;5Etfw">February 3&comma; 2021<&sol;a><&sol;p><&sol;blockquote>&NewLine;<p><script async src&equals;"https&colon;&sol;&sol;platform&period;twitter&period;com&sol;widgets&period;js" charset&equals;"utf-8"><&sol;script><&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The increase in emerging variants with the potential to reduce the efficacy of first-generation Covid-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic&comma;” the companies said in a statement&period;<&sol;p>&NewLine;<p>The announcement came as public health officials around the world raise concerns about new virus variants that are more contagious or resistant to existing vaccines&period;<&sol;p>&NewLine;<p>While viruses mutate constantly&comma; most of the changes cause little concern&comma; but scientists are closely tracking the mutations to make sure they quickly identify variants of concern&period;<&sol;p>&NewLine;<p>Authorities in England are this week conducting house to-house coronavirus testing in targeted communities in a bid to snuff out a new variant before it spreads widely and undermines a nationwide vaccination programme&period;<&sol;p>&NewLine;<p>Officials want to test about 80&comma;000 people in eight areas where the variant&comma; first identified in South Africa&comma; is believed to be spreading after a handful of cases were found in people who had no contact with the country or anyone who travelled there&period;<&sol;p>&NewLine;<p>Public health officials are concerned about the variant first identified in South Africa because it contains a mutation of the virus’s characteristic spike protein targeted by existing vaccines&period; The mutation may mean the vaccines offer less protection against the variant&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We believe that next-generation vaccines will be crucial in the continued fight against Covid-19&comma;” GSK chief executive Emma Walmsley said in the statement&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;This new collaboration builds on our existing relationship with CureVac and means that together&comma; we will combine our scientific expertise in mRNA and vaccine development to advance and accelerate the development of new Covid-19 vaccine candidates&period;”<&sol;p>&NewLine;<p>Meanwhile&comma; China has announced a plan to provide 10 million vaccine doses to developing nations through the global Covax initiative&period;<&sol;p>&NewLine;<p>Foreign Ministry spokesman Wang Wenbin said Beijing is responding to a request from the World Health Organisation as developing countries seek to fill shortages predicted to run until March&period;<&sol;p>&NewLine;<p>Mr Wang called it an important policy decision by China to ensure equitable distribution of vaccines and to promote international co-operation in efforts against the pandemic&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ed17c0d8d2a">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ed17c0d8d2a'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version